Please use this identifier to cite or link to this item: https://doi.org/10.1002/jps.21860
Title: Oral sulfasalazine as a clinical BCRP probe substrate: Pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration
Authors: Adkison, K.K.
Vaidya, S.S.
Lee, D.Y.
Koo, S.H. 
Li, L.
Mehta, A.A.
Gross, A.S.
Polli, J.W.
Humphreys, J.E.
Lou, Y.
Lee, E.J.D.
Keywords: ABC transporters
Clinical pharmacokinetics
Drug interactions
Metabolite kinetics
Pharmacogenetics
Issue Date: Feb-2010
Source: Adkison, K.K., Vaidya, S.S., Lee, D.Y., Koo, S.H., Li, L., Mehta, A.A., Gross, A.S., Polli, J.W., Humphreys, J.E., Lou, Y., Lee, E.J.D. (2010-02). Oral sulfasalazine as a clinical BCRP probe substrate: Pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. Journal of Pharmaceutical Sciences 99 (2) : 1046-1062. ScholarBank@NUS Repository. https://doi.org/10.1002/jps.21860
Abstract: This study evaluated the utility of oral sulfasalazine as a probe substrate for Breast Cancer Resistance Protein (BCRP; ABCG2) activity by assessing the impact of genetic variation or coadministration of an inhibitor (pantoprazole) on plasma and urine pharmacokinetics of sulfasalazine and metabolites. Thirty-six healthy male subjects prescreened for ABCG2 421CC (reference activity), CA, and AA (lower activity) genotypes (N = 12 each) received a single 500mg oral dose of enteric coated sulfasalazine alone, with 40mg pantoprazole, or with 40mg famotidine (gastrointestinal pH control) in a 3-period, single fixed sequence, crossover design. No significant difference in sulfasalazine or metabolite pharmacokinetics in 421AA or CA compared to 421CC subjects was found; however, high inter-subject variability was observed. Geometric mean (95% CI) sulfasalazine plasma AUC(0-∞) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) μg h/mL, and Cmax were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) μg/mL for CC, CA, and AA subjects, respectively. Pantoprazole and famotidine did not affect sulfasalazine pharmacokinetics in any genotypic cohort. These results suggest that the pharmacokinetics of oral, enteric-coated 500mg sulfasalazine are not sufficiently sensitive to ABCG2 genetic variation or inhibitors to be useful as a clinical probe substrate of BCRP activity. © 2009 Wiley-Liss, Inc. and the American Pharmacists Association.
Source Title: Journal of Pharmaceutical Sciences
URI: http://scholarbank.nus.edu.sg/handle/10635/128791
ISSN: 00223549
DOI: 10.1002/jps.21860
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

34
checked on Jan 17, 2018

WEB OF SCIENCETM
Citations

28
checked on Jan 17, 2018

Page view(s)

5
checked on Jan 12, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.